Benefits Associated with an Early Hemoglobin Response to Epoetin Alfa Therapy in the Treatment of Chemotherapy-Related Anemia

Authors: Susana M. Campos MD, MPH * , Mei Sheng Duh MPH, ScD * , Patrick Lefebvre MA * and James Rosberg PhD, MBA *
View More View Less
  • * From the Dana-Farber Cancer Institute, Boston, Massachusetts, USA, Analysis Group, Inc., Boston, Massachusetts, USA, and Groupe d'Analyse, Ltée, Montréal, Québec, Canada.

Although previous studies have recognized that timely correction of anemia is desirable, no published research quantifies the association between the timeliness of the hemoglobin rise and patients' outcomes. This study evaluates whether anemic patients with cancer who are receiving chemotherapy and who experienced an early response to epoetin alfa (≥ 1 g/dL hemoglobin increase at the end of 4 weeks of treatment) experienced better clinical and drug utilization outcomes compared with patients who did not experience an early response. Three large, open-label, community studies of epoetin alfa for the treatment of chemotherapy-related anemia were retrospectively analyzed to assess the association of early hemoglobin response to subsequent transfusion requirements, subsequent hemoglobin response, quality of life, and epoetin alfa dosage administered over the study. Two epoetin alfa dosing regimens were evaluated: 10,000 units 3 times weekly with potential escalation to 20,000 units, and 40,000 units once weekly with potential escalation to 60,000 units. In all studies, patients who experienced an early hemoglobin response had statistically lower subsequent transfusion requirements, higher rates of subsequent hemoglobin response, shorter time to hemoglobin response, better improvements in quality of life scores, and lower average weekly epoetin alfa dose than patients who did not experience an early hemoglobin response. Similar proportions of patients experienced early response in the 3-times weekly and once-weekly epoetin alfa regimens. This ad hoc analysis found that early hemoglobin response to epoetin alfa therapy was associated with improved clinical benefits and drug utilization. Early hemoglobin response may therefore be considered as a desired goal of epoetin alfa therapies.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Susana M. Campos, MD, MPH, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115. E-mail: Susana_Campos@dfci.harvard.edu.
  • 1

    Coiffier B, Guastalla JP, Pujade-Lauraine E. Predicting cancer-associated anemia in patients receiving non-platinum chemotherapy: results of a retrospective survey. Eur J Cancer 2001;37:16171623.

    • Search Google Scholar
    • Export Citation
  • 2

    Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:16161634.

  • 3

    Cella D. Factors influencing quality of life in cancer patents: anemia and fatigue. Semin Oncol 1998;25:4346.

  • 4

    Curt GA. Impact of fatigue on quality of life in oncology patients. Semin Hematol 2000;37:1417.

  • 5

    Sobrero A, Puglisi F, Guglielmi A. Fatigue: a main component of anemia symptomatology. Semin Oncol 2001;28:1518.

  • 6

    Visovsky C, Schneider SM. Cancer-related fatigue. J Issues Nurs 2003;8:123.

  • 7

    Berger AM, Higginbotham P. Correlates of fatigue during and following adjuvant breast cancer chemotherapy: a pilot study. Oncol Nur Forum 2000;27:14431448.

    • Search Google Scholar
    • Export Citation
  • 8

    Berger AM, VonEssen S, Kuhn BR. Adherence, sleep, and fatigue outcomes after adjuvant breast cancer chemotherapy: results of a feasibility intervention study. Oncol Nurs Forum 2003;30:513522.

    • Search Google Scholar
    • Export Citation
  • 9

    Demetri GD, Kris M, Wade J. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:34123425.

    • Search Google Scholar
    • Export Citation
  • 10

    Gabrilove JL, Cleeland CS, Livingston RB. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:28752882.

    • Search Google Scholar
    • Export Citation
  • 11

    Vansteenkiste J, Pirker R, Massuti B. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:12111220.

    • Search Google Scholar
    • Export Citation
  • 12

    Glaspy JA, Tchekmedyian NS. Darbepoetin alfa administered every two weeks alleviates anemia in cancer patients receiving chemotherapy. Oncology 2002;16[suppl 10]:2329.

    • Search Google Scholar
    • Export Citation
  • 13

    Hedenus M, Hansen S, Taylor K. Randomized, dose-finding study of darbepoetin alfa in anemic patients with lymphoproliferative malignancies. Br J Haematol 2002;119:7986.

    • Search Google Scholar
    • Export Citation
  • 14

    Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin-α increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 2003;98:10721079.

    • Search Google Scholar
    • Export Citation
  • 15

    Glaspy J, Bukowski R, Steinberg D. Impact of therapy with epoetin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997;15:12181234.

    • Search Google Scholar
    • Export Citation
  • 16

    Fahrbach KR, Frame D, Scheye R. Comparison of anemia treatment outcomes in patients with cancer receiving epoetin alfa and darbepoetin alfa [abstract]. Blood 2003;102:510b. Abstract 5774.

    • Search Google Scholar
    • Export Citation
  • 17

    Mark TL, McKenzie SR, Piech CT. Better early and overall hematologic outcomes and lower drug cost with epoetin alfa compared to darbepoetin alfa. Blood 2003;102:510b. Abstract 5772.

    • Search Google Scholar
    • Export Citation
  • 18

    Papatheofanis F, Fahrbach K, Mark T. A pooled analysis of observational data evaluating usage and clinical outcomes of erythropoietic agents [abstract]. Proc Am Soc Clin Oncol 2004;23:552. Abstract 6144.

    • Search Google Scholar
    • Export Citation
  • 19

    Jaresko G, Gibson G, Dominquez O. Evaluation of the use and outcomes of erythropoietic proteins for the treatment of chemotherapy-induced anemia in the university-affiliated ambulatory setting [abstract]. Pharmacotherapy 2003;23:1345. Abstract 86.

    • Search Google Scholar
    • Export Citation
  • 20

    Landy S. Migraine throughout the life cycle: treatment through the ages. Neurology 2004;9 [suppl 2]:S2S8.

  • 21

    ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health-Syst Pharm 1999;56:729764.

    • Search Google Scholar
    • Export Citation
  • 22

    Cella D, The Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997;34[suppl 2]:1319.

    • Search Google Scholar
    • Export Citation
  • 23

    Oberhoff C, Neri B, Amadori D. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncolo 1998;9:255260.

    • Search Google Scholar
    • Export Citation
  • 24

    Gillespie TW. Anemia in cancer: therapeutic implications and interventions. Cancer Nurs 2003;26:119128.

  • 25

    Ness PM, Rothko K. Principles of red blood cell transfusion. In: Hoffman R, Benz EJ, Shattil SJ, eds. Hematology: Basic Principles and Practice, 3rd ed. Philadelphia: Churchill Livingstone;2000:22412247.

    • Search Google Scholar
    • Export Citation
  • 26

    National Comprehensive Cancer Network, Cancer and Treatment-Related Anemia, Clinical Practice Guidelines, Version 2.2004. Available at: http://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf. Accessed September 2004.

    • Search Google Scholar
    • Export Citation
  • 27

    Rizzo D, Lichtin LE, Woolf SH. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:40834107.

    • Search Google Scholar
    • Export Citation
  • 28

    Glaspy JA, Jadeja JS, Justice G. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Brit J Cancer 2002;87:268276.

    • Search Google Scholar
    • Export Citation
  • 29

    Jumbe NL, Doshi S, Yao B. Darbepoetin alfa rational dose/schedule evaluation based on quantitative understanding of erythropoiesis for early and sustained alleviation of anemia. Presented at the 39th Annual Meeting of ASCO; May 31-June 3, 2003,; Chicago, Illinois.

    • Search Google Scholar
    • Export Citation
  • 30

    Schwartzberg L, Hesketh P, Rossi. Optimizing management of chemotherapy-induced anemia: a combined analysis of data using a darbepoetin alfa front loading/maintenance approach. Presented at the 39th Annual Meeting of ASCO; May 31-June 3, 2003; Chicago, Illinois.

    • Search Google Scholar
    • Export Citation
  • 31

    Berndt E, Kallich J, McDermott A. Reduction in anemia and fatigue are associated with improvements in productivity in cancer patients receiving chemotherapy. Pharmacoeconomics 2005;23:505514.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 124 52 1
PDF Downloads 15 14 0
EPUB Downloads 0 0 0